Aug 2021 – Present · 4 yrs 9 mos · Taipei, Taipei City, Taiwan · Hybrid

• Develops and delivers an intensive course of Health Technology Assessment (1 credit, 16 hours, course code MGH7054). The same time guest lecturing in 1) Evidence-based Global Health Policy Making, 2) Human Anatomy, and 3) Exploratory Learning
• Awarded Excellence in Teaching Academic Year 2024 National Taiwan University

Feb 2020 – Present · 6 yrs 3 mos

Sep 2018 – Apr 2025 · 6 yrs 7 mos

Apr 2018 – Present · 8 yrs 1 mo · Central Singapore

Jul 2017 – Present · 8 yrs 10 mos · Singapore

Jun 2017 – Apr 2025 · 7 yrs 10 mos · Greater Chicago Area

• As a member of this group of more than 40,000 oncology professionals, I am now part of a multidisciplinary effort to conquer cancer through scientific research and education.

Jun 2017 – Jan 2020 · 2 yrs 7 mos · Central Singapore

Mar 2017 – Mar 2019 · 2 yrs · Hong Kong

Jan 2017 – Present · 9 yrs 4 mos

• Support the Asia Consortium on the new initiatives, health science/policy and some other activities within the Asia Consortium by providing scientific knowledge and skills
• Contribute ideas and suggestions, such as providing new initiatives on HEOR, new trend of HEOR or healthcare policy in Singapore or Asia-Pacific, suggestions for Asia-Pacific Conference plenary topics

Jul 2016 – Dec 2019 · 3 yrs 5 mos · Singapore

• Prepared and implemented comprehensive molecular diagnostics strategy to facilitate achievement by planning cost-effective operations and market development activities in Southeast Asia (SEA) Responsible for coordinating medical and commercial input for full lifecycle management
• Responsible for validating cancer diagnostics strategy with key SEA KOLs
• Responsible for ensuring compliance and alignment of local, regional, and global genomic profiling strategy, plans and activities within SEA
• Responsible for providing input to global genomic profiling strategy to ensure SEA requirements are presented
• Accountable for developing and maintaining annual budget requests and ensuring individual service/product budgets are being managed and tracked
• Responsible for maintaining open communication and cooperation with functional leaders to ensure knowledge exchange and sharing of good practice
• Close collaboration with global commercial lead and active participation in global commercial team meetings to ensure alignment and drive future regional development plans
• Manages a high performing scientific and medical team to support pre- and post-testing consultation for cancer specialists
• Communicates and maintains trust relationships with clinical and research leaders, shareholders, business partners and health regulatory authorities in Southeast Asia
• Achievement: 1) co-initiated Thailand’s first Molecular Tumour Board meeting at Bumrungrad International Hospital, Jul 2017; 2) provides cancer genomic profiling services to more than 100 hospitals across Southeast Asia within 2 years; 3) secured 4 grant-supported cancer translational research projects with Singapore’s leading cancer centres (NCCS & NCIS) within 2 years; 4) awarded Asia Pacific’s Leadership in Product Strategy in Molecular Diagnostics by Frost & Sullivan 2017; 5) awarded Executive of the Year 2018 (Biotech) by Singapore Business Review

Jun 2016 – Jun 2017 · 1 yr

• Led ISPOR-Singapore to conduct fundamental research and capability-building activities directed towards the promotion of pharmacoeconomics and outcomes research in Singapore; endeavored to facilitate scholarly and engaging discussion on far-reaching topics, such as personalized medicine and stakeholder management in health technologies, among researchers, biopharmaceutical companies, healthcare practitioners, and decision-makers. On behalf of ISPOR-S, I worked closely with academics and healthcare industries to generate interests in using value-based clinical and patient report outcomes, such as EQ-5D, to improve healthcare decision making in the changing health regulatory landscape and frontiers in Singapore.

Oct 2014 – Jun 2016 · 1 yr 8 mos

• providing consultation for companies and ministries on health trends and market access issues; building strategic relationships with academic, government officials, and industry sponsors

Nov 2015 – Jul 2016 · 8 mos · Singapore

• The Principal for Health Economics & Outcomes Research (HEOR), Real-World Evidence Solutions (RWE) at IMS Health Asia Pacific, based in Singapore.
• Responsible for helping re-build the HEOR practice and the go to market model for public health in South East Asia. He also spearheads the IMS Health Institute for Healthcare Informatics, which positions IMS Health strongly amongst clinicians/key opinion leaders and academics thereby helping in our broader RWE strategy.
• Major achievement:
• 1.Identify new revenue opportunities at existing and potential clients
• 2.Grow and consolidate HEOR/RWE business in line with financial expectations with accountability
• 3.Be accountable for overall RWE revenue growth and individual sourced revenue target
• 4.Meet assigned revenue targets by developing and delivering insightful, value-added solutions that address complex client issues
• 5.Transition regional HEOR model to non-traditional modality by bringing in new academic alliances and public-private partnerships
• 6.Establish and develop IMS Health Institute for Healthcare Informatics for Southeast Asia
• (the period from Nov 2015 - Feb 2016, Dr. Lai was working for IMS as an external domain expert and consultant)

Apr 2014 – Feb 2016 · 1 yr 10 mos

• Developing courses and expertise specific to health industries in Asia
• Delivering courses in health care business landscape and health policy analysis in Asia
• Linking academic faculty members to industry thought leaders to co-develop industry specific courses and internship or industry attachment programmes in Asia

Aug 2013 – Feb 2016 · 2 yrs 6 mos

• Dr. Allen Lai is the Director of the Institute of Health Economics & Management Asia-Pacific (IHEM Asia-Pacific), ESSEC Business School, where he heads IHEM Asia-Pacific’s efforts in fostering knowledge transfers between academic, policy makers and business communities on health economics issues in the Asia-Pacific region as well as between Europe and Asia.

Sep 2013 – Feb 2016 · 2 yrs 5 mos

• building research capabilities and expertise in health policy and economics; representing ESSEC Asia Pacific in interactions with external parties on health economics issues; managing cross-functional teams and ensuring alignment on sponsors’ objectives; developing and delivering education and training workshops for corporate sponsors, healthcare executives and public officials; conducting a series of tripartite public talks on health, business and society issues; providing consultation for companies and ministries on health trends and market access issues; holding two high level health policy decision makers forums (Shanghai, 2013; Singapore, 2015)

Jun 2013 – Jan 2015 · 1 yr 7 mos · Singapore, UK, India, China, South East Asia

• My research has two priority fields in medical biotechnology in China and India: Regenerative Medicine (Stem cell research; Tissue-engineered wound care); and Stratified/Personalised Medicine (Bioinformatics; Pharmacogenomics). Our research team is to examine the nature and impact of China and India's strategies on the governance of biomedical innovation at national, regional and global levels and the implications for UK policy.

Aug 2010 – Present · 15 yrs 9 mos

Aug 2008 – May 2013 · 4 yrs 9 mos · Singapore

• I obtained my PhD in Public Policy from the Lee Kuan Yew School of Public Policy (LKYSPP), National University of Singapore (NUS), where I was awarded Lee Kuan Yew Scholarship (2007) and a full doctorate research scholarship (2008-2013). My doctorate research focuses on forging collaborative capacity through crisis learning, illustrated through case studies of lead public health institutions in different epidemic networks and health systems to tackle SARS and H1N1 pandemics in Taiwan, Singapore and Hong Kong. During my doctorate research, I have been recently consulted for the following organizations: Health Promotion Bureau (Taiwan), Ateneo School of Government (Philippines), and Economic Research Institute for ASEAN and East Asia (ERIA). In 2010, I was awarded a delegate to NUS Initiative to Improve Health in Asia (NIHA). I have published several articles regarding infectious disease control, and disaster and emergency management in the international peer reviewed top journals, and has been invited for presentations worldwide.

Jan 2004 – Jan 2005 · 1 yr

• Quality Assurance and Process Management in clinical projects and patient treatment; operational logistics to streamline patient flow; designing clinical pathway and lowering likelihood of medical malpractice.

Jan 2000 – Jan 2004 · 4 yrs

• Responsible for arranging operation schedule; handling day-to-day administration and coordination for medical services; allocation medical resources (bed availability, operation room vacancy; equipment turnover), and human resources (arranging patient admission and operation; liaising with hospital administrators on admission and discharge services; schedule conflict resolution; rotation of all resident doctors and medical students); assisting in improving health services before, during, and after hospital accreditation; developing capacity building program for medical and nursing staff on routine and emergency; educating medical students, intern doctors, clerk doctors in the ward round and clinic practices, and reporting their appraisal.

Jan 2004 – Jan 2008 · 4 yrs · Yang Ming Branch

• learning and practicing how to diagnose and treat patients with tumors, cancers, infections, urolithiasis and congenital and/or acquired malfunction in and of genital and urinary systems; assisting in improving health services before, during, and after hospital accreditation; developing capacity building program for medical and nursing staff on routine and emergency; serving on preparedness and response team for various mass events and public health emergencies